A carregar...
In the Biosimilar Marketplace Will There Be 50 Ways to Leave Your Insulin?
The future biosimilar insulin marketplace could be a bane, benefit, or something in between, to patients under our care in the United States. Formulary preferred product status, with or without FDA interchangeability designation, coupled with current and proposed state pharmacy substitution laws may...
Na minha lista:
| Publicado no: | J Diabetes Sci Technol |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5032938/ https://ncbi.nlm.nih.gov/pubmed/26817993 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1932296816629488 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|